Asian Pacific Journal of Cancer Prevention

  • 제15권14호
  • /
  • Pages.5529-5533
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Liposome-mediated Induction of Apoptosis of Human Hepatoma Cells by C-Myc Antisense Phosphorothioate Oligodeoxynucleotide and 5-Fluorouracil

  • 발행 : 2014.07.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The aim of this study was to investigate the effect of a c-myc antisense oligodeoxynucleotide and 5-fluorouracil on the expression of c-myc, invasion and proliferation of HEPG-2 liver cancer cells. Materials and Methods: HEPG-2 cells were treated with lipiosome-mediated c-myc ADSON and 5-fluorouracil. The proliferation inhibition rate and invasion were measured by MTT and invasion assay, respectively. Cell apoptosis was detected by flow cytometry and expression of c-myc by RT-PCR and immunohistochemistry. Results: The proliferation inhibition rate was significantly higher in the antisense oligodeoxynucleotide added-5-fluorouracil group than single antisense oligodeoxynucleotide or 5-fluorouracil group (p<0.05). G0/G1 cells in the antisense oligodeoxynucleotide group and S cells in the 5-fluorouracil groups were significantly increased than that in the control group, respectively (P<0.01). The amplification strips of PCR products in 5-FU, ASODN and combination groups were significantly weaker than that in the control group (P<0.01). The percentage of c-myc-protein-positive cells were significantly lower in antisense oligodeoxynucleotide, 5-fluorouracil and combination groups than that in the control group (P<0.01). Conclusions: A liposome-mediated c-myc antisense oligodeoxynucleotide and 5-fluorouracil can inhibit the proliferation and invasion of liver cancer cells by reducing the expression of c-myc. A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer.

키워드

참고문헌

  1. Albihn A, Johnsen JI, Henriksson MA (2010). MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res, 107, 163-224 https://doi.org/10.1016/S0065-230X(10)07006-5
  2. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012. Available online. Last accessed November 23, 2012.
  3. Barathidasan R, Pawaiya RS, Rai RB, et al (2013). Upregulated myc expression in n-methyl nitrosourea (MNU)-induced rat ma mmary tumours. Asian Pac J Cancer Prev, 14, 4883-9. https://doi.org/10.7314/APJCP.2013.14.8.4883
  4. Doe MR, Ascano JM, Kaur M, et al (2012). Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res, 72. 949-57. https://doi.org/10.1158/0008-5472.CAN-11-2371
  5. Fang YQ, Sun HK, Zhai J, et al (2011). Antitumor Activity of NF-kB Decoy Oligodeoxynucleotides in a Prostate Cancer Cell Line. Asian Pacific J Cancer Prev, 12, 2721-6.
  6. Guo WQ, Li LZ, He ZY, et al (2013). Anti-proliferative Effects of Atractylis lancea (Thunb.) DC. via Down-regulation of the c-myc/hTERT/telomerase pathway in Hep-G2 cells. Asian Pac J Cancer Prev, 14, 6363-7. https://doi.org/10.7314/APJCP.2013.14.11.6363
  7. Hayashi D (1994). Study on the expression of oncogene mRNA in hepatocellular carcinoma using in situ hybridization technique. Nihon Geka Gakkai Zasshi. 95, 814-22.
  8. Hemann MT, Bric A, Teruya-Feldstein J, et al (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436, 807-11. https://doi.org/10.1038/nature03845
  9. Howlader N, Noone AM, Krapcho M, et al (2011), eds.:SEER Cancer Statistics Review, 1975-2008. Bethesda, Md: National Cancer Institute, 2011. Also available online. Last accessed July, 31, 2012.
  10. Jain M, Arvanitis C, Chu K, et al (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science, 297, 102-4. https://doi.org/10.1126/science.1071489
  11. Jansen B, Zangemeister-Wittke U (2002). Antisense therapy for cancer--the time of truth. Lancet Oncol, 3, 672-83. https://doi.org/10.1016/S1470-2045(02)00903-8
  12. Jin J, Huang M, Wei HL et al (2002). Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel (7402). World J Gastroenterol, 8. 1029-34.
  13. Karlsson A, Giuriato S, Tang F, et al (2003). Genomically complex lymphomas undergo sustained tumor regression upon MY inactivation unless they acquire novel chromosomal translocations. Blood, 101, 2797-803. https://doi.org/10.1182/blood-2002-10-3091
  14. Lin CP, Liu CR, Lee CN, et al (2010). Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol, 2. 16-20.
  15. Manner J, Radlwi mmer B, Hohenberger P, et al (2010). MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol, 176, 34-9. https://doi.org/10.2353/ajpath.2010.090637
  16. Monia BP (1997). First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des, 12, 327-39.
  17. Parkin DM, Whelan SL, Ferlay J, et al (1997). eds.:Cancer Incidence in Five Continents. Volume VII. Lyon, France:International Agency for Research on Cancer
  18. Pastorino F, Mumbengegwi DR, Ribatti D, et al (2008). Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release, 126, 85-94. https://doi.org/10.1016/j.jconrel.2007.11.010
  19. Wang B, Hikosaka K, Sultana N, et al (2012). Liver tumor formation by a mutant retinoblastoma protein in the transgenic mice is caused by an upregulation of c-My target genes. Biochem Biophys Res Co mmun, 417, 601-6. https://doi.org/10.1016/j.bbrc.2011.12.014
  20. Wang C, Lisanti MP, Liao DJ (2011). Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1- CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle, 10, 57-67. https://doi.org/10.4161/cc.10.1.14449
  21. Wu SL, Sun ZJ, Yu L, et al (2004). Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol, 10, 3048-52.
  22. Yang Y, Lv QJ, Du QY, et al (2005). Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol, 11, 2491-6. https://doi.org/10.3748/wjg.v11.i16.2491
  23. Yochum GS, Sherrick CM, Macpartlin M, et al (2010). A betacatenin/ TCF- coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA, 107, 145-50. https://doi.org/10.1073/pnas.0912294107

피인용 문헌

  1. Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy vol.16, pp.2, 2017, https://doi.org/10.3892/mmr.2017.6778